Guidance for the care of neuromuscular ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.
Author(s) :
Solé, G [Auteur]
CHU de Bordeaux Pellegrin [Bordeaux]
Salort-Campana, E [Auteur]
Marseille medical genetics - Centre de génétique médicale de Marseille [MMG]
Pereon, Y [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Stojkovic, T [Auteur]
Wahbi, K [Auteur]
AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris]
Cintas, P [Auteur]
Adams, D [Auteur]
Service de Neuroradiologie [CHU de Bicêtre]
Laforet, P [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Tiffreau, Vincent [Auteur]
Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - ULR 7369 - ULR 4488 [URePSSS]
Desguerre, I [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Pisella, L I [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Molon, A [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Attarian, S [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
CHU de Bordeaux Pellegrin [Bordeaux]
Salort-Campana, E [Auteur]
Marseille medical genetics - Centre de génétique médicale de Marseille [MMG]
Pereon, Y [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Stojkovic, T [Auteur]
Wahbi, K [Auteur]
AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris]
Cintas, P [Auteur]
Adams, D [Auteur]
Service de Neuroradiologie [CHU de Bicêtre]
Laforet, P [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Tiffreau, Vincent [Auteur]

Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - ULR 7369 - ULR 4488 [URePSSS]
Desguerre, I [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Pisella, L I [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Molon, A [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Attarian, S [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Journal title :
Revue Neurologique
Abbreviated title :
Rev Neurol (Paris)
Volume number :
176
Pages :
507-515
Publication date :
2020-06-01
ISSN :
0035-3787
English keyword(s) :
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Anti-Bacterial Agents
Antimalarials
Azithromycin
Betacoronavirus
COVID-19
Cardiorespiratory Fitness
Coronavirus Infections
Emergency Treatment
France
Glycogen Storage Disease Type II
Hospitalization
Humans
Hydroxychloroquine
Immune System Diseases
Immunoglobulins, Intravenous
Immunosuppressive Agents
Muscular Atrophy, Spinal
Neuromuscular Diseases
Oligonucleotides
Pandemics
Physical Therapy Modalities
Pneumonia, Viral
Prognosis
RNA, Small Interfering
SARS-CoV-2
Steroids
Withholding Treatment
alpha-Glucosidases
COVID-19
Guidelines
Management
Neuromuscular
Treatment
Angiotensin-Converting Enzyme Inhibitors
Anti-Bacterial Agents
Antimalarials
Azithromycin
Betacoronavirus
COVID-19
Cardiorespiratory Fitness
Coronavirus Infections
Emergency Treatment
France
Glycogen Storage Disease Type II
Hospitalization
Humans
Hydroxychloroquine
Immune System Diseases
Immunoglobulins, Intravenous
Immunosuppressive Agents
Muscular Atrophy, Spinal
Neuromuscular Diseases
Oligonucleotides
Pandemics
Physical Therapy Modalities
Pneumonia, Viral
Prognosis
RNA, Small Interfering
SARS-CoV-2
Steroids
Withholding Treatment
alpha-Glucosidases
COVID-19
Guidelines
Management
Neuromuscular
Treatment
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of emergency measures and a degradation in the ...
Show more >In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of emergency measures and a degradation in the organization of neuromuscular reference centers. In this special context, the French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS) has established guidance in an attempt to homogenize the management of neuromuscular (NM) patients within the French territory. Hospitalization should be reserved for emergencies, the conduct of treatments that cannot be postponed, check-ups for which the diagnostic delay may result in a loss of survival chance, and cardiorespiratory assessments for which the delay could be detrimental to the patient. A national strategy was adopted during a period of 1 to 2months concerning treatments usually administered in hospitalization. NM patients treated with steroid/immunosuppressants for a dysimmune pathology should continue all of their treatments in the absence of any manifestations suggestive of COVID-19. A frequently asked questions (FAQ) sheet has been compiled and updated on the FILNEMUS website. Various support systems for self-rehabilitation and guided exercises have been also provided on the website. In the context of NM diseases, particular attention must be paid to two experimental COVID-19 treatments, hydroxycholoroquine and azithromycin: risk of exacerbation of myasthenia gravis and QT prolongation in patients with pre-existing cardiac involvement. The unfavorable emergency context related to COVID-19 may specially affect the potential for intensive care admission (ICU) for people with NMD. In order to preserve the fairest medical decision, a multidisciplinary working group has listed the neuromuscular diseases with a good prognosis, usually eligible for resuscitation admission in ICU and, for other NM conditions, the positive criteria suggesting a good prognosis. Adaptation of the use of noninvasive ventilation (NIV) make it possible to limit nebulization and continue using NIV in ventilator-dependent patients.Show less >
Show more >In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of emergency measures and a degradation in the organization of neuromuscular reference centers. In this special context, the French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS) has established guidance in an attempt to homogenize the management of neuromuscular (NM) patients within the French territory. Hospitalization should be reserved for emergencies, the conduct of treatments that cannot be postponed, check-ups for which the diagnostic delay may result in a loss of survival chance, and cardiorespiratory assessments for which the delay could be detrimental to the patient. A national strategy was adopted during a period of 1 to 2months concerning treatments usually administered in hospitalization. NM patients treated with steroid/immunosuppressants for a dysimmune pathology should continue all of their treatments in the absence of any manifestations suggestive of COVID-19. A frequently asked questions (FAQ) sheet has been compiled and updated on the FILNEMUS website. Various support systems for self-rehabilitation and guided exercises have been also provided on the website. In the context of NM diseases, particular attention must be paid to two experimental COVID-19 treatments, hydroxycholoroquine and azithromycin: risk of exacerbation of myasthenia gravis and QT prolongation in patients with pre-existing cardiac involvement. The unfavorable emergency context related to COVID-19 may specially affect the potential for intensive care admission (ICU) for people with NMD. In order to preserve the fairest medical decision, a multidisciplinary working group has listed the neuromuscular diseases with a good prognosis, usually eligible for resuscitation admission in ICU and, for other NM conditions, the positive criteria suggesting a good prognosis. Adaptation of the use of noninvasive ventilation (NIV) make it possible to limit nebulization and continue using NIV in ventilator-dependent patients.Show less >
Peer reviewed article :
Oui
Audience :
Non spécifiée
Administrative institution(s) :
Université de Lille
Univ. Artois
Univ. Littoral Côte d’Opale
Univ. Artois
Univ. Littoral Côte d’Opale
Research team(s) :
Activité Physique, Muscle, Santé (APMS)
Submission date :
2021-02-08T18:41:52Z
2021-02-15T08:55:04Z
2021-02-15T08:55:04Z
Files
- 2020_Solé_Rev Neurol.pdf
- Version finale acceptée pour publication (postprint)
- Open access
- Access the document